Evaluation of Safety, Tolerability, and Pharmacokinetics of FBT-002 in Healthy Subjects

The primary objective of this study is to evaluate the **safety** and **tolerance** of the anti-toxin drug FBT-002 in healthy male and female subjects. This is clinically relevant as it aims to ensure that the drug is safe for human use and can be tolerated without adverse effects, which is crucial for its potential application as an **antidote**. The study will also assess changes in blood levels of FBT-002, providing important pharmacokinetic data that can inform dosing and administration strategies.

The clinical trial involves a study population comprising both **male** and **female** participants. The age range of the participants is categorized as **adults**, although specific age limits are not provided. The trial does not focus on a vulnerable population, indicating that the participants are likely in a general state of health without significant vulnerabilities. The total number of participants is not disclosed, as the sponsor has not provided this information. The selection criteria for the trial population, including any lifestyle considerations such as diet or physical activity, are not specified. The study is related to an **antidote**, but further details regarding the medical condition or specific objectives of the trial are not available.

The clinical trial is designed to evaluate the **safety** and tolerance of an anti-toxin drug, FBT-002, in healthy male and female subjects. This is a Phase 1 trial, which is typically the first stage of testing in human subjects and focuses on assessing the drug's safety profile. The trial is structured as a randomized, double-blind, controlled study, ensuring that neither the participants nor the researchers know who is receiving the actual drug versus a placebo, thus minimizing bias. The estimated recruitment start date is December 6, 2023, with the trial expected to conclude by August 31, 2024.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This visit will involve a comprehensive assessment to ensure that participants meet the necessary health standards for inclusion in the trial. Following successful screening, participants will be randomly assigned to receive either the investigational drug or a placebo. Throughout the trial, there will be scheduled follow-up visits to monitor the participants' health, collect blood samples, and assess any changes in blood levels of the drug. These visits are crucial for evaluating the drug's pharmacokinetics and any potential adverse effects.

The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to ensure the safety and well-being of the participants. The expected length of participant involvement will vary depending on the specific protocol of the trial, but it will generally span the duration of the study. Conditions that may lead to early termination from the study include the occurrence of significant adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The trial's design and procedures are meticulously planned to ensure the collection of reliable data while prioritizing participant safety.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is available from the provided data. Consequently, a detailed description of the experimental treatment cannot be provided.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these treatments cannot be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the data. As such, these details cannot be elaborated upon in this context.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, with an estimated recruitment start date of December 6, 2023, and an estimated end date of August 31, 2024. The efficacy assessment will be conducted using predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a systematic approach to collect and analyze data, ensuring that the results are scientifically valid and reliable. The study will adhere to rigorous standards typical of Phase 1 trials, focusing on initial assessments of efficacy alongside safety evaluations. The trial's design and execution will be aligned with clinical research protocols to ensure the integrity and accuracy of the findings.